Current situation (2026-04-03)
Supply has stabilised significantly compared to the peak shortage periods of 2022–2023. The government's restriction on off-label weight loss prescribing (October 2024) reduced demand pressure, allowing more stock to reach diabetes patients who need it. However, some pharmacies still experience intermittent stock issues, particularly for certain dose strengths.
Why shortages happened
- Explosive global demand: GLP-1 medications became the fastest-growing drug class in history. Global demand massively outpaced Novo Nordisk's manufacturing capacity.
- Off-label weight loss prescribing: Before restrictions, up to 80% of Australian Ozempic prescriptions were estimated to be off-label for weight loss — diverting supply from diabetes patients.
- Complex manufacturing: Biological medications like semaglutide can't be scaled up quickly. New manufacturing facilities take 3–5 years to build.
- Global allocation: Australia competes with the US, Europe, and other markets for limited supply.
What to do if you can't get your Ozempic
If you have type 2 diabetes:
- Ask your pharmacist to check stock at nearby pharmacies
- Ask your pharmacist to order it — supply is usually available within a few days
- Discuss alternative diabetes medications with your doctor as a temporary bridge
- Register with the TGA's medicine shortage reports for updates
If you were using Ozempic for weight loss:
Since off-label prescribing is now restricted, you'll need to switch to an approved weight loss medication:
- Wegovy — same ingredient at higher dose, approved for weight loss
- Mounjaro — different mechanism, higher average weight loss
Will shortages end?
Novo Nordisk has invested over $6 billion in expanding manufacturing capacity, including new facilities in Denmark and the US. Combined with the off-label prescribing restrictions, supply is expected to continue improving through 2026. However, as Wegovy uptake grows, new supply pressures may emerge.